We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 197

Mayo on the side? The Canadian Patent Office issues new examination guidelines for medical diagnostic methods
  • Borden Ladner Gervais LLP
  • Canada
  • July 17 2015

On June 29, 2015, the Canadian Intellectual Property Office (CIPO) issued a long-awaited Practice Notice PN 2015-02("Notice") on the subject of


Court of Appeal gives guidance on sound prediction issues
  • Borden Ladner Gervais LLP
  • Canada
  • July 15 2015

The Federal Court of Appeal (FCA) upheld a recent infringement decision finding a patent to be invalid due to inutility (decision here; summary here


Astrazeneca Canada Inc. v. Apotex Inc., 2015 FC 671
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2015

The parties moved under Rule 397 to modify the terms of the judgment in the proceeding, previously reported as 2015 FC 322 and summarized in our


Court grants judicial review of minister of health’s decision
  • Borden Ladner Gervais LLP
  • Canada
  • January 16 2014

Apotex brought this application for judicial review of a decision of the Therapeutic Products Directorate (TPD) refusing to review Apotex’


Novartis Pharmaceuticals Canada Inc. v. Teva Canada Limited, 2015 FC 770
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2015

Novartis has obtained an order prohibiting the Minister from providing an NOC to Teva for EXJADE. At the hearing, the issues were narrowed by Teva


Minister’s decision to grant NOA to generic company set aside, as the generic did not comply with the NOC regulations
  • Borden Ladner Gervais LLP
  • Canada
  • January 19 2015

In this proceeding, Pfizer sought to judicially review the Minister of Health’s decision to grant Teva a NOC for exemestane. A company called GMP


Formulation patent allegations of non-infringement, obviousness and lack of utility justified
  • Borden Ladner Gervais LLP
  • Canada
  • March 2 2015

Servier sought a prohibition order against Apotex in relation to its DIAMICRON MR gliclazide product. The application was dismissed. The patent at


Ramipril section 8 appeal dismissed from the bench by the Supreme Court of Canada
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

On Monday, April 20, 2015, the Supreme Court of Canada heard the appeal of 2014 FCA 68, relating to the issue of damages under section 8 of the


Patent claiming one medicinal ingredient not found to have sufficient product specificity to be listed against a drug containing two medicinal ingredients
  • Borden Ladner Gervais LLP
  • Canada
  • April 29 2015

The Court of Appeal has dismissed Viiv Healthcare’s appeal of a Prothonotary’s decision (2014 FC 328; upheld by the Federal Court: 2014 FC 893


Patent held invalid for not meeting promise of improved therapeutic profile
  • Borden Ladner Gervais LLP
  • Canada
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and